Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection
about
Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigenPrevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasisA review of adjuvants for Leishmania vaccine candidates.Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?Adjuvants for Leishmania vaccines: from models to clinical application.Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).Development of Leishmania vaccines: predicting the future from past and present experience.Cutaneous leishmaniasis: progress towards a vaccine.Immunostimulatory responses to crude extracts of Warburgia ugandensis (Sprague) subsp ugandensis (Canellaceae) by BALB/c mice infected with Leishmania major.Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Protective immunity and vaccination against cutaneous leishmaniasis.Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses.IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB/c mice.Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.
P2860
Q28539852-D57DA175-107C-41F3-98DE-637A66F47233Q33946716-BAF10403-DDED-42D9-B26B-DC021E4413B9Q34008104-3D0CCBA4-438E-4A9A-8A37-039DE7030BFCQ34008441-B790807C-A585-42B0-9583-FD606887F6EAQ34647684-F2FE551E-6E6B-4552-A847-626D27335C16Q35702943-9835338D-65E4-4C89-BD31-67FBAFAFFE30Q35884264-012402AB-6F11-4700-BBF3-406ABAF26E7AQ35928348-D9A24B5C-EF06-4A58-A52C-FCC19354E963Q36021357-DC079889-4479-4F2B-B069-8A76E158ADE8Q36680084-E0632FD1-2DC0-4EA7-9525-95001522DD8DQ36700453-E13462DD-3BF8-4CB9-BA7F-71A59D9821A9Q37290119-32938691-0A95-4324-8CFF-5A5B40ADB0E7Q37624078-8E56A528-C75B-4D4F-BC1F-CBA1DF650F23Q37773297-88FFF20E-7EDA-4553-8C96-95EEB57165D0Q37965724-9926ADB3-961B-4BA5-99B9-EE6F4F09E4A9Q38015852-D0B644B8-AAA6-4256-BAC1-A667180621CFQ39495272-A1A8AD69-6324-4B81-BBC5-D7C76BE570E6Q41868154-9EF651EC-BFEA-4C41-A253-CAC90F8230ECQ42653980-F2764C5E-CFE7-4DDC-9140-EDE2F5E8A58FQ47732162-E62A0533-1A91-41C3-9D34-F98F3639E2B9Q53884236-B2B26EB3-08E0-4F35-A630-F0946CDE3EB2Q53963953-D462327A-AA30-44C2-8A00-3C68F542D15F
P2860
Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Vervet monkeys vaccinated with ...... ed against challenge infection
@ast
Vervet monkeys vaccinated with ...... ed against challenge infection
@en
Vervet monkeys vaccinated with ...... ed against challenge infection
@nl
type
label
Vervet monkeys vaccinated with ...... ed against challenge infection
@ast
Vervet monkeys vaccinated with ...... ed against challenge infection
@en
Vervet monkeys vaccinated with ...... ed against challenge infection
@nl
prefLabel
Vervet monkeys vaccinated with ...... ed against challenge infection
@ast
Vervet monkeys vaccinated with ...... ed against challenge infection
@en
Vervet monkeys vaccinated with ...... ed against challenge infection
@nl
P2093
P2860
P1476
Vervet monkeys vaccinated with ...... ed against challenge infection
@en
P2093
P2860
P304
P356
10.1128/IAI.69.1.245-251.2001
P407
P577
2001-01-01T00:00:00Z